Par Pharmaceuticals announced that the Food and Drug Administration (FDA) has approved Ethacrynate Sodium for Injection, the first generic version of Aton Pharma's Sodium Edecrin.
Unichem Pharmaceuticals issued a voluntary nationwide recall of Hydrochlorothiazide 25mg tablets after the discovery of a Clopidogrel tablet in a bottle.
Taking spironolactone alongside the antibiotic trimethoprim-sulfamethoxazole can cause blood potassium to rise to potentially life-threatening levels.
Research indicates that spironolactone may reduce rehospitalizations and 30-day mortality in patients with acute heart failure (AHF).
Baxter announced that the FDA has approved Flexbumin (albumin [human]) 5% solution for the treatment of hypovolemia, hypoalbuminemia due to general causes, burns, and for use during cardiopulmonary bypass surgery as a component of the pump prime.
Hispanics became much more likely to take their heart medicines after Medicare's prescription drug benefit plan was launched in 2006, but there was only a small increase seen among black patients.
An increasing number of people suffer from conditions typically associated with aging, including heart failure (HF) and lower urinary tract symptoms (LUTS).
The USPSTF has found that insufficient evidence to evaluate the benefits and harms of multivitamins and most single- or paired-nutrient supplements for the prevention of cardiovascular disease and cancer.
Quality, patient outcomes, and costs must all be assessed in determining the appropriateness of noninvasive cardiovascular imaging.
Getting to the Heart of the Matter: A Review of Potential Drug Interactions With Cardiac Medications
Cardiac drug interactions make up almost 25% of all preventable adverse drug reactions.
Patients with adrenal tumors of intermediate phenotype or subclinical Cushing's syndrome are at increased risk of cardiovascular events and mortality compared to those with stable non-secreting adrenal incidentalomas.
Pulmonary congestion can predict risk of death and cardiac events in patients with end-stage renal disease undergoing dialysis.
Patients with coronary artery disease who receive percutaneous coronary intervention (PCI) have increased platelet reactivity after the procedure despite antiplatelet therapy.
The positive predictive value (PPV) of the exercise treadmill test (ETT) for coronary artery disease (CAD) in women is altered significantly by age and certain exercise responses.
Beta blockers (BBs) are effective as an early prophylactic pharmacologic treatment for patients with mild hypertrophic cardiomyopathy (HC) who have exercise-induced left ventricular outflow tract (LVOT) obstruction.
In patients with coronary heart disease, aerobic exercise and the antidepressant sertraline are both associated with reduced depressive symptoms when compared to placebo, and they both tend to improve heart rate variability.
Under high altitude (HA) hypoxemia conditions, exercise performance seems to be better preserved with nebivolol than carvedilol.
Diagonal ear lobe crease (DELC) is independently and significantly associated with the prevalence, extent, and severity of coronary artery disease (CAD).
For patients with dilated cardiomyopathy, treatment with an autologous bone marrow-derived, expanded multi-cell product, ixmyelocel-T, is well tolerated and associated with improved symptoms at one year.
For healthy adults ascending from low to high altitude, ibuprofen effectively reduces the incidence and severity of acute mountain sickness, compared with placebo.
In patients with stable intermittent claudication due to peripheral arterial disease, low-dose aspirin appears to work as well as clopidogrel when given in conjunction with walking rehabilitation to improve initial claudication distance (ICD) and absolute claudication distance (ACD).
Elevated homocysteine levels are not associated with a greater risk of coronary heart disease when considering unpublished data, suggesting publication bias.
Medtronic's Resolute Integrity Drug-Eluting Stent (DES) has been approved by the US Food and Drug Administration for people with coronary artery disease (CAD).
Shire announced that Firazyr (icatibant injection), a selective bradykinin B2 receptor antagonist, has been approved for the treatment of acute attacks of hereditary angioedema (HAE) in adults ≥18 years of age.